Ranbaxy’s Path Cleared For Authorized Prilosec Launch
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The 1.5 billion dollar Indian drug-maker Ranbaxy launched an authorized generic version of anti-ulcer drug omeprazole 40 mg in the U.S. as part of an agreement reached earlier with the gastric ulcer and Zollinger-Ellison syndrome treatment's innovator AstraZeneca
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).